Bayer sues Lupin over generic birth control pill
- Earthquake of magnitude 6.0 hits Afghanistan, tremors felt in north india
- Modi sarkar on right track to bring 'achche din': LK Advani
- Army officer injured in encounter with militants in J&K's Kupwara district
- Modi in Malaysia: Religion should be delinked from terror, says PM
- US 'will not relent' in Islamic State campaign, says Barack Obama
German drugmaker Bayer has filed a lawsuit in the United States against Indian generic drug maker Lupin, to prevent it from selling a version of Bayer's birth-control pill Natazia in the US.
In the lawsuit, filed on Nov. 28, Bayer said that Lupin is preparing to bring a copy of the Natazia pill, also called Qlaira, to U.S. markets even though Bayer's U.S. patent on the pill runs through 2026.
The complaint said Bayer would be entitled to an award of damages and treble damages for any commercial sales of the generic product.
Lupin declined to comment on the lawsuit. "We do not comment on on-going litigations as a matter of policy," said Lupin spokesperson Shamsher Gorawara.
Natazia is approved in the U.S. as a contraceptive and for the treatment of heavy menstrual bleeding.
Birth-control is one of the most important businesses for Bayer's pharmaceuticals arm, with contraceptive sales of 1.1 billion euros in 2011.
Bayer Pharma AG v Lupin Ltd. and Lupin Pharmaceuticals Inc. (Case 1:12-cv-01592-UNA) was filed with the U.S. District Court, District of Delaware.
Company INFO More on Bayer's pharmaceuticals
Mutual Funds Check for top funds
- Open channels of communication are vital for democracy and governance
- Slogans should be backed with appropriate strategies, else they remain showbiz
- Ideas seem to be the BJP’s enemy, whether from within or from without
- No country is ready to send boots on the ground, thus ensuring the survival of the IS
- Bad monsoon memories
- Across the aisle: A flat growth rate indicates India's economy is in poor shape